Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (PIRS) on July 31, 2019. The filing discloses corporate governance changes, specifically the election of a new director and associated compensatory arrangements. The company is incorporated in Nevada and trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel and compensation details.
Material Changes
The primary material change reported is the appointment of Maya Said, Sc.D. to the Board of Directors as a Class II Director, effective July 31, 2019. Dr. Said was appointed to the Nominating and Corporate Governance Committee and the Science and Technology Committee.
Compensatory Arrangements and Management Commentary
In connection with her election, the following compensation package was granted to Dr. Said:
- Stock Option: A non-statutory option to purchase up to 30,000 shares of common stock at an exercise price of $5.50 per share (the closing price on July 31, 2019). The option vests one year after the grant date, subject to continued service.
- Cash Retainers:
- Annual Director Retainer: $35,000
- Nominating and Corporate Governance Committee Retainer: $3,750
- Science and Technology Committee Retainer: $5,000
- Indemnification: Dr. Said will enter into a standard indemnification agreement covering expenses, judgments, fines, and settlement amounts arising from her service as a director.
Dr. Said brings significant experience in oncology policy, market access, and strategy from previous roles at Novartis, Sanofi, Boston Consulting Group, and Celsius Therapeutics.
Investor Verification Checklist
- Verify the vesting schedule and exercise terms of the 30,000 share option granted to Dr. Said.
- Confirm the total annual cash compensation obligation for the new director ($43,750).
- Review the attached press release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.